Tango Therapeutics (TNGX) EBIAT (2020 - 2025)
Tango Therapeutics has reported EBIAT over the past 6 years, most recently at -$38.7 million for Q4 2025.
- Quarterly results put EBIAT at -$38.7 million for Q4 2025, down 2.86% from a year ago — trailing twelve months through Dec 2025 was -$101.6 million (up 22.03% YoY), and the annual figure for FY2025 was -$101.6 million, up 22.03%.
- EBIAT for Q4 2025 was -$38.7 million at Tango Therapeutics, down from $15.9 million in the prior quarter.
- Over the last five years, EBIAT for TNGX hit a ceiling of $15.9 million in Q3 2025 and a floor of -$39.9 million in Q1 2025.
- Median EBIAT over the past 5 years was -$26.8 million (2023), compared with a mean of -$25.0 million.
- Biggest five-year swings in EBIAT: tumbled 951806.78% in 2021 and later surged 154.46% in 2025.
- Tango Therapeutics' EBIAT stood at -$22.0 million in 2021, then crashed by 31.82% to -$29.1 million in 2022, then dropped by 5.86% to -$30.8 million in 2023, then decreased by 22.45% to -$37.7 million in 2024, then decreased by 2.86% to -$38.7 million in 2025.
- The last three reported values for EBIAT were -$38.7 million (Q4 2025), $15.9 million (Q3 2025), and -$38.9 million (Q2 2025) per Business Quant data.